99.00 €
Brak w magazynie
1-3 business days
Cagrilintide is a product that stands out as a completely new approach, to control sugar levels, cravings and, consequently, to fight obesity. These two active compounds, used together, offer a powerful solution for those struggling with excess weight. Our Cagrilintide + Semaglutide product offers an effective solution in getting rid of obesity, accelerates weight loss, prevents the recurrence of excess weight. Take a look at its specifications and choose a solution to get a slim figure.
Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist. Initially developed for the treatment of type 2 diabetes, Semaglutide has shown significant benefits in weight reduction. Its mechanism of action involves mimicking the hormone GLP-1, which increases insulin secretion, inhibits glucagon release and slows gastric emptying. These actions combine to improve glycemic control and reduce appetite, facilitating weight loss. On the market, it is primarily known by the trade name Ozempic.
Cagrilintide is a new amylin analog. Amylin is a hormone secreted along with insulin by the pancreas, playing a key role in regulating glucose levels after meals and promoting feelings of satiety. By mimicking amylin, Cagrilintide helps slow gastric emptying and increase the feeling of satiety, aiding weight loss.
You can read more about the topic in the research paper:
https://pubmed.ncbi.nlm.nih.gov/36883831/

Also check out the versions in penie!
Used together, Semaglutide and Cagrilintide work synergistically to increase weight loss and improve glycemic control. GLP-1 receptor agonist action of Semaglutide complements amylin-mimicking properties of Cagrilintide, providing a dual approach to regulating appetite and keeping blood sugar levels low.
The efficacy of Semaglutide and Cagrilintide combination therapy has been widely reported in clinical trials. In one key studies it has been shown that Patients receiving combination therapy experienced significantly greater weight loss compared to those on monotherapy or placebo. In addition, improvements in HbA1c levels and other metabolic parameters were observed, underscoring the combination's potential for treating diabetes.
Semaglutide binds to GLP-1 receptors on pancreatic beta cells, stimulating insulin secretion in a glucose-dependent manner. It also reduces glucagon secretion, which helps lower blood glucose levels. Moreover, Semaglutide's action on the brain reduces appetite and increases feelings of satiety.
Cagrilintide, mimicking amylin, delays gastric emptying and promotes a feeling of fullness. This action reduces food intake, contributing to weight loss. Moreover, amylin analogs have been shown to reduce post-meal glucose spikes, further aiding glycemic control.
So you get a product that will work with double the force, allowing you to lose weight faster.
While weight loss is undoubtedly a significant benefit, the combination of Semaglutide and Cagrilintide also offers other advantages. Improved insulin sensitivity, reduced liver fat and improved cardiovascular health are all things you get when using a combination of the two products.
The combination of Semaglutide and Cagrilintide represents a breakthrough advance in the treatment of obesity. By addressing multiple pathways involved in appetite regulation and glucose control, the combination therapy offers a comprehensive and effective approach to weight loss.
All descriptions are based on scientific sources and are informative.
INTENDED FOR RESEARCH PURPOSES!
All properties mentioned above are observed with laboratory tests, not done on humans, and are for informational purposes only. Any information contained in the descriptions has not been approved by GIS, GIF or EFSA. The substance is not a drug, food product or dietary supplement, consequently it is not suitable for human consumption. The product qualifies as a chemical reagent / reference material approved for marketing in the EU. It can only be used for scientific research. For other information on the agent, please refer to the Material Safety Data Sheet, which is available for review. The products are available only to institutions or individuals who are associated with research or laboratory activities.
CAGRILINTIDE + SEMAGLUTIDE 2mg+2mg vial
| 5 gwiazdek | 87 | 87% |
| 4 gwiazdki | 9 | 9% |
| 3 gwiazdki | 3 | 3% |
| 2 gwiazdki | 1 | 1% |
| 1 gwiazdka | 0% |
Posso acquistare senza ricetta?
11/10 😉
weniger cravings und mehr energie alles gut
tbh i feel less hungry and more energetic now
Support mega freundlich, schnell antw, echt top
didnt expect much but honestly works pretty good
bestellung kam fix alles ok kein probs
Sehr schnelle Lieferung und alles problemlos.
Very happy. This is my 4th order. Reta works - I can confirm! Very satisfied.
Best peptides store, highly recommended, professional service and smooth transaction. Nice 🤝
About
DHL Shipping
FedEx Shipping
Check out our other suggestions. Choose the product best suited to your goals.
Join the Novell newsletter and gain access to the latest news from the world of peptides, reagents and research. Be the first to receive alerts on new product launches, exclusive promotions and industry news. We support the development of science - stay up-to-date with us and benefit from expert knowledge and top-notch solutions.
Novell is a European distributor of specialized reagents and peptides with purity above 99%. We offer laboratory-grade, research-proven products tailored to meet the needs of modern scientific research. With retail and wholesale sales and efficient e-commerce logistics, we provide fast and reliable delivery throughout Europe.
JOSCUR LIMITED Company
Registration number: 77335383
DE main warehouse
© 2025 TIRZEPATYD.EU